3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
2
Sponsor Class
OTHER
3
INDUSTRY
2
NIH
1
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
92
Neoplasm Metastasis
10
Neoplasms
9
Breast Diseases
4
Advanced Breast Cancer
3
Recurrence
2
Neoplasms by Site
2
Carcinoma, Renal Cell
2
Breast Neoplasms, Male
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Tuberous Sclerosis
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Diseases
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Post Menopausal Women With Early Breast Cancer
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Multiple Endocrine Neoplasia Type 1
1
Mammary Neoplasms, Animal
1
Lymphoma
1
Lung Neoplasms
1
Lung Diseases
1
Lethal Congenital Contracture Syndrome 2
1
Kidney Neoplasms
1
Invasive Early Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Interventions
exemestane
2
Letrozole
2
seviteronel
1
sargramostim
1
ribociclib
1
methyl N-acetylsibirosaminide
1
elacestrant
1
Trastuzumab
1
Tamoxifen
1
Suspensions
1
Receptor Protein-Tyrosine Kinases
1
Presenilin-1
1
Pemetrexed
1
Leuprolide
1
Injections
1
HER2 peptide (369-377)
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Goserelin
1
Fentanyl
1
Anastrozole
1
90Y-octreotide, DOTA-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Breast Neoplasms, Male
×
exemestane
×
Clear all
NCT05827081
2026-06-03
Adjuvant WIDER
Novartis
Phase 3
Recruiting
1,400 enrolled
NCT06492616
2026-05-27
ELEGANT
Stemline Therapeutics, Inc.
Phase 3
Recruiting
4,220 enrolled